Hemoperfusión con dispositivo CytoSorb en paciente con COVID-19
| Autor: | Jaime Gómez Ayala, Jorge Eduardo Rico Fontalvo, Greisy González, Alonso Pomares Lara, César Ferrer Mercado, Rodrigo Daza Arnedo, Emilio Rey Vela, Víctor Leal Martínez, Nehomar Eduardo Pájaro Galvis, María Raad Sarabia, Emilio Abuabara Franco, Christian Pérez Calvo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Mechanical ventilation
medicine.medical_specialty business.industry medicine.medical_treatment Organ dysfunction Acute kidney injury General Medicine medicine.disease Asymptomatic Clinical trial Infectious disease (medical specialty) Medicine Renal replacement therapy medicine.symptom business Cytokine storm Intensive care medicine |
| Zdroj: | Revista Colombiana de Nefrología. 8:e515 |
| ISSN: | 2500-5006 2389-7708 |
| DOI: | 10.22265/acnef.8.1.515 |
| Popis: | Introduction: COVID 19 is an infectious disease caused by the RNA virus SARS-COV 2, which has a very heterogeneous clinical presentation, ranging from asymptomatic people to critically ill patients, with cytokine storm, acute respiratory distress, organ dysfunction and death. Current therapies are aimed at reducing the impact of the inflammatory cascade, among which we find Hemoadsorption technologies such as the Cytosorb membrane. Methodology: next, we lend the case of a patient in the fourth decade of life, who consulted with severe COVID 19, which showed an evident clinical and biochemical improvement after using the Cytosorb device. Being the only documented patient in Colombia, who has been used this device in conjunction with prolonged intermittent renal replacement therapy, with favorable clinical outcomes. Conclusions: Hemoadsorption therapies, and within these the Cytosorb technology, seem to be promising treatment strategies in the management of patients with severe COVID 19 and cytokine storm. This treatment should be done early, ideally in the first 24 hours after the injury is established, based on clinical and laboratory criteria. It must be taken into account that the moment of initiation of therapy is key, since after 48 hours the probability of success decreases. Here we present the case of a patient with severe COVID, managed with Cytosorb therapy, which showed a clear clinical and biochemical improvement. This is due to avoiding the need for invasive mechanical ventilation, weaning from vasopressor support, and a decrease in inflammatory markers. However, more clinical trials are needed to allow us to evaluate the effectiveness of Hemoadsorption therapies in this type of patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|